Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
16
XFOR Quote, Financials, Valuation and Earnings
Last price:
$3.80
Seasonality move
:
14.77%
Day range:
$3.25 - $3.81
52-week range:
$1.35 - $26.83
Dividend yield:
0%
P/E ratio:
0.70x
P/S ratio:
1.54x
P/B ratio:
4.61x
Volume:
509K
Avg. volume:
1.4M
1-year change:
-70.71%
Market cap:
$284.2M
Revenue:
$2.6M
EPS (TTM):
-$10.01
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
XFOR
X4 Pharmaceuticals, Inc.
|
$1.9M | -$0.84 | 38.65% | -93.6% | $7.38 |
|
ADVM
Adverum Biotechnologies, Inc.
|
-- | -$1.68 | -100% | -16.52% | $4.90 |
|
ALT
Altimmune, Inc.
|
$560 | -$0.27 | -88.8% | -21.83% | $17.88 |
|
HIMS
Hims & Hers Health, Inc.
|
$579.8M | $0.23 | 28.34% | 73.71% | $44.82 |
|
PFE
Pfizer Inc.
|
$16.5B | $0.63 | -1.98% | 745.84% | $29.04 |
|
RXRX
Recursion Pharmaceuticals, Inc.
|
$19.4M | -$0.38 | 464.97% | -35.01% | $6.33 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
XFOR
X4 Pharmaceuticals, Inc.
|
$3.25 | $7.38 | $284.2M | 0.70x | $0.00 | 0% | 1.54x |
|
ADVM
Adverum Biotechnologies, Inc.
|
$4.17 | $4.90 | $92.1M | -- | $0.00 | 0% | 89.16x |
|
ALT
Altimmune, Inc.
|
$5.32 | $17.88 | $554.6M | -- | $0.00 | 0% | 21,107.47x |
|
HIMS
Hims & Hers Health, Inc.
|
$37.07 | $44.82 | $8.4B | 68.53x | $0.00 | 0% | 4.16x |
|
PFE
Pfizer Inc.
|
$25.57 | $29.04 | $145.4B | 14.90x | $0.43 | 6.73% | 2.32x |
|
RXRX
Recursion Pharmaceuticals, Inc.
|
$4.66 | $6.33 | $2.4B | -- | $0.00 | 0% | 42.75x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
XFOR
X4 Pharmaceuticals, Inc.
|
55.66% | -0.336 | 89.95% | 5.25x |
|
ADVM
Adverum Biotechnologies, Inc.
|
267.19% | 1.088 | 89.25% | 0.58x |
|
ALT
Altimmune, Inc.
|
7.89% | 0.693 | 4.41% | 16.79x |
|
HIMS
Hims & Hers Health, Inc.
|
65.81% | 5.905 | 8.66% | 1.49x |
|
PFE
Pfizer Inc.
|
39.94% | 0.301 | 42.51% | 0.81x |
|
RXRX
Recursion Pharmaceuticals, Inc.
|
7.29% | 1.657 | 3.43% | 4.27x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
XFOR
X4 Pharmaceuticals, Inc.
|
$1.4M | -$27.5M | -84.9% | -279.19% | -1558.58% | -$27.8M |
|
ADVM
Adverum Biotechnologies, Inc.
|
-$465K | -$47M | -152.8% | -558.69% | -2922.1% | -$28.3M |
|
ALT
Altimmune, Inc.
|
-$22K | -$20.9M | -53.6% | -56.24% | -417180% | -$11.9M |
|
HIMS
Hims & Hers Health, Inc.
|
$365.2M | $18.2M | 13.77% | 25.63% | 3.04% | $79M |
|
PFE
Pfizer Inc.
|
$11.2B | $5.5B | 6.35% | 10.84% | 33.21% | $4B |
|
RXRX
Recursion Pharmaceuticals, Inc.
|
-$22.9M | -$172.2M | -72.69% | -80.23% | -3327.58% | -$117.6M |
X4 Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns XFOR or ADVM?
Adverum Biotechnologies, Inc. has a net margin of -1689.24% compared to X4 Pharmaceuticals, Inc.'s net margin of -2713.4%. X4 Pharmaceuticals, Inc.'s return on equity of -279.19% beat Adverum Biotechnologies, Inc.'s return on equity of -558.69%.
Company Gross Margin Earnings Per Share Invested Capital XFORX4 Pharmaceuticals, Inc.78.81% -$0.69 $139M ADVMAdverum Biotechnologies, Inc.-- -$2.03 $33.3M -
What do Analysts Say About XFOR or ADVM?
X4 Pharmaceuticals, Inc. has a consensus price target of $7.38, signalling upside risk potential of 126.92%. On the other hand Adverum Biotechnologies, Inc. has an analysts' consensus of $4.90 which suggests that it could grow by 17.51%. Given that X4 Pharmaceuticals, Inc. has higher upside potential than Adverum Biotechnologies, Inc., analysts believe X4 Pharmaceuticals, Inc. is more attractive than Adverum Biotechnologies, Inc..
Company Buy Ratings Hold Ratings Sell Ratings XFORX4 Pharmaceuticals, Inc.3 0 0 ADVMAdverum Biotechnologies, Inc.2 4 0 -
Is XFOR or ADVM More Risky?
X4 Pharmaceuticals, Inc. has a beta of 0.421, which suggesting that the stock is 57.861% less volatile than S&P 500. In comparison Adverum Biotechnologies, Inc. has a beta of 0.869, suggesting its less volatile than the S&P 500 by 13.055%.
-
Which is a Better Dividend Stock XFOR or ADVM?
X4 Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adverum Biotechnologies, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. X4 Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Adverum Biotechnologies, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XFOR or ADVM?
X4 Pharmaceuticals, Inc. quarterly revenues are $1.8M, which are larger than Adverum Biotechnologies, Inc. quarterly revenues of --. X4 Pharmaceuticals, Inc.'s net income of -$29.8M is higher than Adverum Biotechnologies, Inc.'s net income of -$47.7M. Notably, X4 Pharmaceuticals, Inc.'s price-to-earnings ratio is 0.70x while Adverum Biotechnologies, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for X4 Pharmaceuticals, Inc. is 1.54x versus 89.16x for Adverum Biotechnologies, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XFORX4 Pharmaceuticals, Inc.1.54x 0.70x $1.8M -$29.8M ADVMAdverum Biotechnologies, Inc.89.16x -- -- -$47.7M
-
Which has Higher Returns XFOR or ALT?
Altimmune, Inc. has a net margin of -1689.24% compared to X4 Pharmaceuticals, Inc.'s net margin of -380280%. X4 Pharmaceuticals, Inc.'s return on equity of -279.19% beat Altimmune, Inc.'s return on equity of -56.24%.
Company Gross Margin Earnings Per Share Invested Capital XFORX4 Pharmaceuticals, Inc.78.81% -$0.69 $139M ALTAltimmune, Inc.-440% -$0.21 $201.5M -
What do Analysts Say About XFOR or ALT?
X4 Pharmaceuticals, Inc. has a consensus price target of $7.38, signalling upside risk potential of 126.92%. On the other hand Altimmune, Inc. has an analysts' consensus of $17.88 which suggests that it could grow by 249.8%. Given that Altimmune, Inc. has higher upside potential than X4 Pharmaceuticals, Inc., analysts believe Altimmune, Inc. is more attractive than X4 Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings XFORX4 Pharmaceuticals, Inc.3 0 0 ALTAltimmune, Inc.5 1 1 -
Is XFOR or ALT More Risky?
X4 Pharmaceuticals, Inc. has a beta of 0.421, which suggesting that the stock is 57.861% less volatile than S&P 500. In comparison Altimmune, Inc. has a beta of -0.029, suggesting its less volatile than the S&P 500 by 102.89%.
-
Which is a Better Dividend Stock XFOR or ALT?
X4 Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Altimmune, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. X4 Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Altimmune, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XFOR or ALT?
X4 Pharmaceuticals, Inc. quarterly revenues are $1.8M, which are larger than Altimmune, Inc. quarterly revenues of $5K. X4 Pharmaceuticals, Inc.'s net income of -$29.8M is lower than Altimmune, Inc.'s net income of -$19M. Notably, X4 Pharmaceuticals, Inc.'s price-to-earnings ratio is 0.70x while Altimmune, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for X4 Pharmaceuticals, Inc. is 1.54x versus 21,107.47x for Altimmune, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XFORX4 Pharmaceuticals, Inc.1.54x 0.70x $1.8M -$29.8M ALTAltimmune, Inc.21,107.47x -- $5K -$19M
-
Which has Higher Returns XFOR or HIMS?
Hims & Hers Health, Inc. has a net margin of -1689.24% compared to X4 Pharmaceuticals, Inc.'s net margin of 2.63%. X4 Pharmaceuticals, Inc.'s return on equity of -279.19% beat Hims & Hers Health, Inc.'s return on equity of 25.63%.
Company Gross Margin Earnings Per Share Invested Capital XFORX4 Pharmaceuticals, Inc.78.81% -$0.69 $139M HIMSHims & Hers Health, Inc.60.97% $0.06 $1.7B -
What do Analysts Say About XFOR or HIMS?
X4 Pharmaceuticals, Inc. has a consensus price target of $7.38, signalling upside risk potential of 126.92%. On the other hand Hims & Hers Health, Inc. has an analysts' consensus of $44.82 which suggests that it could grow by 20.9%. Given that X4 Pharmaceuticals, Inc. has higher upside potential than Hims & Hers Health, Inc., analysts believe X4 Pharmaceuticals, Inc. is more attractive than Hims & Hers Health, Inc..
Company Buy Ratings Hold Ratings Sell Ratings XFORX4 Pharmaceuticals, Inc.3 0 0 HIMSHims & Hers Health, Inc.2 8 1 -
Is XFOR or HIMS More Risky?
X4 Pharmaceuticals, Inc. has a beta of 0.421, which suggesting that the stock is 57.861% less volatile than S&P 500. In comparison Hims & Hers Health, Inc. has a beta of 2.414, suggesting its more volatile than the S&P 500 by 141.424%.
-
Which is a Better Dividend Stock XFOR or HIMS?
X4 Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hims & Hers Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. X4 Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Hims & Hers Health, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XFOR or HIMS?
X4 Pharmaceuticals, Inc. quarterly revenues are $1.8M, which are smaller than Hims & Hers Health, Inc. quarterly revenues of $599M. X4 Pharmaceuticals, Inc.'s net income of -$29.8M is lower than Hims & Hers Health, Inc.'s net income of $15.8M. Notably, X4 Pharmaceuticals, Inc.'s price-to-earnings ratio is 0.70x while Hims & Hers Health, Inc.'s PE ratio is 68.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for X4 Pharmaceuticals, Inc. is 1.54x versus 4.16x for Hims & Hers Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XFORX4 Pharmaceuticals, Inc.1.54x 0.70x $1.8M -$29.8M HIMSHims & Hers Health, Inc.4.16x 68.53x $599M $15.8M
-
Which has Higher Returns XFOR or PFE?
Pfizer Inc. has a net margin of -1689.24% compared to X4 Pharmaceuticals, Inc.'s net margin of 21.32%. X4 Pharmaceuticals, Inc.'s return on equity of -279.19% beat Pfizer Inc.'s return on equity of 10.84%.
Company Gross Margin Earnings Per Share Invested Capital XFORX4 Pharmaceuticals, Inc.78.81% -$0.69 $139M PFEPfizer Inc.67.15% $0.62 $154.8B -
What do Analysts Say About XFOR or PFE?
X4 Pharmaceuticals, Inc. has a consensus price target of $7.38, signalling upside risk potential of 126.92%. On the other hand Pfizer Inc. has an analysts' consensus of $29.04 which suggests that it could grow by 13.57%. Given that X4 Pharmaceuticals, Inc. has higher upside potential than Pfizer Inc., analysts believe X4 Pharmaceuticals, Inc. is more attractive than Pfizer Inc..
Company Buy Ratings Hold Ratings Sell Ratings XFORX4 Pharmaceuticals, Inc.3 0 0 PFEPfizer Inc.7 15 1 -
Is XFOR or PFE More Risky?
X4 Pharmaceuticals, Inc. has a beta of 0.421, which suggesting that the stock is 57.861% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.
-
Which is a Better Dividend Stock XFOR or PFE?
X4 Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.73% to investors and pays a quarterly dividend of $0.43 per share. X4 Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.
-
Which has Better Financial Ratios XFOR or PFE?
X4 Pharmaceuticals, Inc. quarterly revenues are $1.8M, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. X4 Pharmaceuticals, Inc.'s net income of -$29.8M is lower than Pfizer Inc.'s net income of $3.6B. Notably, X4 Pharmaceuticals, Inc.'s price-to-earnings ratio is 0.70x while Pfizer Inc.'s PE ratio is 14.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for X4 Pharmaceuticals, Inc. is 1.54x versus 2.32x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XFORX4 Pharmaceuticals, Inc.1.54x 0.70x $1.8M -$29.8M PFEPfizer Inc.2.32x 14.90x $16.7B $3.6B
-
Which has Higher Returns XFOR or RXRX?
Recursion Pharmaceuticals, Inc. has a net margin of -1689.24% compared to X4 Pharmaceuticals, Inc.'s net margin of -3135.32%. X4 Pharmaceuticals, Inc.'s return on equity of -279.19% beat Recursion Pharmaceuticals, Inc.'s return on equity of -80.23%.
Company Gross Margin Earnings Per Share Invested Capital XFORX4 Pharmaceuticals, Inc.78.81% -$0.69 $139M RXRXRecursion Pharmaceuticals, Inc.-442.74% -$0.36 $1.1B -
What do Analysts Say About XFOR or RXRX?
X4 Pharmaceuticals, Inc. has a consensus price target of $7.38, signalling upside risk potential of 126.92%. On the other hand Recursion Pharmaceuticals, Inc. has an analysts' consensus of $6.33 which suggests that it could grow by 35.91%. Given that X4 Pharmaceuticals, Inc. has higher upside potential than Recursion Pharmaceuticals, Inc., analysts believe X4 Pharmaceuticals, Inc. is more attractive than Recursion Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings XFORX4 Pharmaceuticals, Inc.3 0 0 RXRXRecursion Pharmaceuticals, Inc.1 6 0 -
Is XFOR or RXRX More Risky?
X4 Pharmaceuticals, Inc. has a beta of 0.421, which suggesting that the stock is 57.861% less volatile than S&P 500. In comparison Recursion Pharmaceuticals, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock XFOR or RXRX?
X4 Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Recursion Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. X4 Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Recursion Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XFOR or RXRX?
X4 Pharmaceuticals, Inc. quarterly revenues are $1.8M, which are smaller than Recursion Pharmaceuticals, Inc. quarterly revenues of $5.2M. X4 Pharmaceuticals, Inc.'s net income of -$29.8M is higher than Recursion Pharmaceuticals, Inc.'s net income of -$162.3M. Notably, X4 Pharmaceuticals, Inc.'s price-to-earnings ratio is 0.70x while Recursion Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for X4 Pharmaceuticals, Inc. is 1.54x versus 42.75x for Recursion Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XFORX4 Pharmaceuticals, Inc.1.54x 0.70x $1.8M -$29.8M RXRXRecursion Pharmaceuticals, Inc.42.75x -- $5.2M -$162.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
69
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
47
PSTG alert for Dec 4
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
41
SMX alert for Dec 4
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
43
HY alert for Dec 4
Hyster-Yale, Inc. [HY] is up 1.92% over the past day.
